MX2009012716A - Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. - Google Patents

Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.

Info

Publication number
MX2009012716A
MX2009012716A MX2009012716A MX2009012716A MX2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A
Authority
MX
Mexico
Prior art keywords
modulators
phenylpyrrolidines
new disubstituted
cortical
catecholaminergic neurotransmission
Prior art date
Application number
MX2009012716A
Other languages
English (en)
Spanish (es)
Inventor
Lars Swanson
Nicholas Waters
Clas Sonesson
Fredrik Pettersson
Susanna Waters
Original Assignee
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab
Publication of MX2009012716A publication Critical patent/MX2009012716A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Pyrrole Compounds (AREA)
MX2009012716A 2007-06-05 2008-06-04 Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. MX2009012716A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94199307P 2007-06-05 2007-06-05
SE0701386 2007-06-05
PCT/EP2008/056912 WO2008148799A1 (en) 2007-06-05 2008-06-04 New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
MX2009012716A true MX2009012716A (es) 2009-12-14

Family

ID=39672106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012716A MX2009012716A (es) 2007-06-05 2008-06-04 Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.

Country Status (11)

Country Link
US (1) US20100197760A1 (enExample)
EP (1) EP2155669B1 (enExample)
JP (1) JP2010529080A (enExample)
CN (1) CN101711234A (enExample)
AT (1) ATE508110T1 (enExample)
AU (1) AU2008258597A1 (enExample)
CA (1) CA2689692A1 (enExample)
DE (1) DE602008006720D1 (enExample)
MX (1) MX2009012716A (enExample)
NZ (1) NZ581363A (enExample)
WO (1) WO2008148799A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5444535B2 (ja) 2007-06-05 2014-03-19 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン
JP5621087B2 (ja) 2008-11-24 2014-11-05 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な3−フェニル−アゼチジン誘導体
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての3−フェニル−3−メトキシピロリジン誘導体
KR101885190B1 (ko) * 2011-03-31 2018-08-06 셰브런 유.에스.에이.인크. 탈랍 촉매 안정성 및 윤활유 수율을 개선하기 위한 신규 방법 및 촉매 시스템

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) * 1959-03-17 Substituted amino alcohols
US364414A (en) * 1887-06-07 Gael hollweg
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
CA2105666C (en) 1991-04-17 2006-02-14 Kjell Anders Ivan Svensson New centrally acting substituted phenylazacycloalkanes
US5129962A (en) * 1991-10-22 1992-07-14 International Business Machines Corporation Tacky, no-clean thermally dissipated soldering flux
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
TWI308976B (en) * 2003-02-14 2009-04-21 Chunghwa Picture Tubes Ltd Process and structure of linquid crystal panel with one drop fill
PL217630B1 (pl) * 2003-04-24 2014-08-29 Incyte Corp Pochodne azaspiroalkanów, kompozycja farmaceutyczna oraz zastosowanie związku
EP1669350B1 (en) * 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
KR100690854B1 (ko) * 2005-11-08 2007-03-09 엘지전자 주식회사 멀티태스킹이 가능한 휴대용 단말기 및 그의 멀티태스킹처리방법
US8329704B2 (en) * 2005-12-21 2012-12-11 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use in MCH-1 mediated diseases
US20080070649A1 (en) * 2006-09-06 2008-03-20 Uchida Toshi K Free Space Optical Interconnections in Cellular Telephone Handsets

Also Published As

Publication number Publication date
JP2010529080A (ja) 2010-08-26
WO2008148799A1 (en) 2008-12-11
ATE508110T1 (de) 2011-05-15
CA2689692A1 (en) 2008-12-11
EP2155669A1 (en) 2010-02-24
AU2008258597A1 (en) 2008-12-11
US20100197760A1 (en) 2010-08-05
CN101711234A (zh) 2010-05-19
NZ581363A (en) 2011-10-28
EP2155669B1 (en) 2011-05-04
DE602008006720D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
MX2009012787A (es) Nuevas fenilpirrolidinas disustituidas como moduladores de neurotransmision catecolaminergica cortical.
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
PH12012500939A1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY157192A (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP2498609A4 (en) SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY160907A (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
EA201171063A1 (ru) Фармацевтические составы олмесартана
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
UY31760A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
UA104152C2 (ru) Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии
MX2009012716A (es) Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.
NZ737451A (en) Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CL2012000650A1 (es) Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras.

Legal Events

Date Code Title Description
FG Grant or registration